Related references
Note: Only part of the references are listed.Restricted Clonality and Limited Germinal Center Reentry Characterize Memory B Cell Reactivation by Boosting
Luka Mesin et al.
CELL (2020)
Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine
Lisa Henss et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections
Sabrina Schrauf et al.
FRONTIERS IN IMMUNOLOGY (2020)
Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort
In-Kyu Yoon et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial
Nina Wressnigg et al.
LANCET INFECTIOUS DISEASES (2020)
B cell memory: building two walls of protection against pathogens
Munir Akkaya et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates
Shannan L. Rossi et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics
Katie L. Winarski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development
Giovanni Rezza et al.
PLOS NEGLECTED TROPICAL DISEASES (2019)
IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody
Simone I. Richardson et al.
PLOS PATHOGENS (2019)
Recent Progress in Vaccine Development Against Chikungunya Virus
Shan Gao et al.
FRONTIERS IN MICROBIOLOGY (2019)
Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses
Matthew Zirui Tay et al.
FRONTIERS IN IMMUNOLOGY (2019)
Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes
Julie M. Fox et al.
SCIENCE IMMUNOLOGY (2019)
Antibody glycosylation in inflammation, disease and vaccination
Galit Alter et al.
SEMINARS IN IMMUNOLOGY (2018)
Chikungunya Virus Strains Show Lineage-Specific Variations in Virulence and Cross-Protective Ability in Murine and Nonhuman Primate Models
Rose M. Langsjoen et al.
MBIO (2018)
Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response
Jean-Louis Palgen et al.
SCIENTIFIC REPORTS (2018)
Broad and long-lasting immune protection against various Chikungunya genotypes demonstrated by participants in a cross-sectional study in a Cambodian rural community
Heidi Auerswald et al.
EMERGING MICROBES & INFECTIONS (2018)
A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
Bronwyn M. Gunn et al.
CELL HOST & MICROBE (2018)
Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane
Jing Jin et al.
CELL HOST & MICROBE (2018)
Serological Cross Reactivity between Zika and Dengue Viruses in Experimentally Infected Monkeys
Shailendra Mani et al.
VIROLOGICA SINICA (2018)
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial
Emil C. Reisinger et al.
LANCET (2018)
Use of Urea Wash ELISA to Distinguish Zika and Dengue Virus Infections
Wen-Yang Tsai et al.
EMERGING INFECTIOUS DISEASES (2018)
Regulation of antibody effector functions through IgG Fc N-glycosylation
Isaak Quast et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Global distribution and environmental suitability for chikungunya virus, 1952 to 2015
E. O. Nsoesie et al.
EUROSURVEILLANCE (2016)
Development of Vaccines for Chikungunya Fever
Jesse H. Erasmus et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus
Wenqian He et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Long-Lasting Immune Protection and Other Epidemiological Findings after Chikungunya Emergence in a Cambodian Rural Community, April 2012
Beatriz Galatas et al.
PLOS NEGLECTED TROPICAL DISEASES (2016)
The Potential Benefits of HPV Vaccination in Previously Infected Women
John T. Schiller
EBIOMEDICINE (2016)
Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology
Amy W. Chung et al.
CELL (2015)
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial
Katrin Ramsauer et al.
LANCET INFECTIOUS DISEASES (2015)
Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis
Jing Jin et al.
CELL REPORTS (2015)
High Rate of Subclinical Chikungunya Virus Infection and Association of Neutralizing Antibody with Protection in a Prospective Cohort in The Philippines
In-Kyu Yoon et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Influenza-Specific Antibody-Dependent Cellular Cytotoxicity: Toward a Universal Influenza Vaccine
Sinthujan Jegaskanda et al.
JOURNAL OF IMMUNOLOGY (2014)
Exposure of Epitope Residues on the Outer Face of the Chikungunya Virus Envelope Trimer Determines Antibody Neutralizing Efficacy
Rachel H. Fong et al.
JOURNAL OF VIROLOGY (2014)
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
Lee-Jah Chang et al.
LANCET (2014)
Affinity Enhancement of Antibodies: How Low-Affinity Antibodies Produced Early in Immune Responses Are Followed by High-Affinity Antibodies Later and in Memory B-Cell Responses
Herman N. Eisen
CANCER IMMUNOLOGY RESEARCH (2014)
IgG subclasses and allotypes: from structure to effector functions
Gestur Vidarsson et al.
FRONTIERS IN IMMUNOLOGY (2014)
Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model
Lucas Y. H. Goh et al.
CLINICAL IMMUNOLOGY (2013)
A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus
Samantha Brandler et al.
VACCINE (2013)
Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein
Yiu-Wing Kam et al.
EMBO MOLECULAR MEDICINE (2012)
Early Appearance of Neutralizing Immunoglobulin G3 Antibodies Is Associated With Chikungunya Virus Clearance and Long-term Clinical Protection
Yiu-Wing Kam et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Longitudinal Analysis of the Human Antibody Response to Chikungunya Virus Infection: Implications for Serodiagnosis and Vaccine Development
Yiu-Wing Kam et al.
JOURNAL OF VIROLOGY (2012)
Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus
Manish Kumar et al.
VACCINE (2012)
Fc-Glycosylation of IgG1 is Modulated by B-cell Stimuli
Jun Wang et al.
MOLECULAR & CELLULAR PROTEOMICS (2011)
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection
Wataru Akahata et al.
NATURE MEDICINE (2010)
Dengue virus neutralization is modulated by IgG antibody subclass and Fcγ receptor subtype
W. W. Shanaka I. Rodrigo et al.
VIROLOGY (2009)
FactoMineR: An R package for multivariate analysis
Sebastien Le et al.
JOURNAL OF STATISTICAL SOFTWARE (2008)
Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine
MJ Hepburn et al.
VACCINE (2006)
Repeated immunization induces the increase in fucose content on antigen-specific IgG N-linked oligosaccharides
NX Guo et al.
CLINICAL BIOCHEMISTRY (2005)
Share Paper
